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Abstract 
Background: Streptokinase is a bacterial protein produced by different beta hemolytic streptococci and widely 
used in thrombolytic treatment. The main disadvantage of using streptokinase is antibody formation which 
causes allergic reaction to neutralize effects of streptokinase therapy. Aim of this study was investigate of 
recombinant mutant streptokinase fibrinolytic activity. 
Materials and Methods: In this study recombinant mutant streptokinase without 42 amino acids from the C 
terminal region was purified by affinity S-Tag column chromatography and its fibrinolytic activity was studied. 
Results: The concentration of expressed and purified protein was 10 mg/ml. Its enzyme activity was assayed 
using zymography, radial caseinolytic activity and fibrin plate test methods and estimated quantitatively by 
casein digestion method compared to a commercial form. 
Conclusion: It was found that this product had the more volume and more enzymatic activity. 
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Blood clots development (thrombosis), in the 
circulatory system, leading to blockage of blood 
vessels and consequences death. Hemostatic system 
suppresses normal development of blood clots in 
normal circulation, but result of incomplete 
hemostasis, are pulmonary embolism, deep venous 
thrombosis and acute myocardial infarction
1
. To 
prevent clot formation, thrombolytic agents such as 
streptokinase (SK), Urokinase and tissue 
plasminogen activator are used
2
. The streptokinase 
(EC 22.99.4.3) is produced by strains of beta 
hemolytic Streptococci. The enzyme consists of a 
single chain polypeptide activates the plasminogen 
directly and its fibrinolytic activity
3
. The 
streptokinase contains 414 amino acids (47Kda), its 
temperature, optimized pH and isoelectric point are 
37-27°C, 7, and 4.7 respectively
3-6
. Plasminogen 
activation by streptokinase related to bacterial 
species
7
. The Streptokinase made of multi-domain 
structure (alfa, beta, and gamma) with different 
functional properties
8
. The γ domain is essential for 
plasminogen activation and α and β domains involved 
in formation of streptokinase-plasminogen complex
9
. 
The N-terminal domain (1- 59 amino acids) with lower 




C-terminal domain play a role in plasminogen 
activation
11,12
 and Aspartic acid 41 and Histidine 48 
are important in plasminogen-streptokinase 
connection
13
. Shortly after discovery of fibrinolytic 
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The main disadvantage of using streptokinase is 
antigenicity of this protein. The antibodies cause 
allergic reaction to neutralize effects of streptokinase 
therapy
15
. Five antigenic region include amino acids 
1- 13, 14- 127, 1- 253, 120- 353, 353- 414 have been 
identified in the molecule
16, 17
. There is evidence 
about immunodominant epitope presence on the C-
terminal region of natural streptokinase molecule. 
The mut-C42 mutant, which lacks 42 C-terminal 
amino acids, have been shown to lower levels of 
antigenicity
18,19
. Sera anti-streptokinase antibody 
level in mutant streptokinase consumers is lower than 
that in the normal streptokinase consumers
20
. We 
have studied mutant streptokinase fibrinolytic 
activity in this paper. 
Methods 
The recombinant pGEMEX -1 vector contained 
mutant streptokinase gene
21
 was digested by SacI and 
BamHI restriction enzymes and released gene 
subcloned into pET32a. Top10 and BL21 (DE3) E. 
coli strains were used for transformation and gene 
expression respectively. Recombinant protein was 
expressed according to previously described 
method
22
. Recombinant protein was purified by 
affinity chromatography using S-Tag purification kit 
flowed by using sodium thiocyanate
23
. Dialysis 
tubing procedure was used to remove urea and 
refolding the protein. Protein was dialyzed against 1x 
PBS buffer (containing 10 mM disodium phosphate, 




Fibrinolytic activity assay 
Zymography 
A polyacrylamide gel (12% separating and 5% 
stacking) was prepared and kept in the refrigerator 
for 18 hours. Loading buffer without 2ME was used 
for electrophoresis. Electrophoresis was performed 
using 1x PBS at 4°C. Gel was flood in 1% Triton 
X100 for 2 hours to eliminate SDS (SDS causes 
enzyme denaturation). The gel washed with water for 
three times and incubated in 1x PBS pH 8 at 37°C for 
2 h. Enzyme activity was determined after staining 




Radial Caseinolytic activity 
A mixture contained 1.2% agarose, 1% skim milk, 100 
microliter of human plasma and 1xPBS was prepared. 
Some wells with 5 mm diameter were created at 
appropriate intervals using sterile Pasteur pipette. Five 
mg (100 microliter) of commercial drug streptokinase 
as standard and 5 mg (100 microliter) of purified 
recombinant protein were poured in wells and 
incubated for 12 hours at 37°C. Clear zone around the 
sample and standard wells were created by lysed 
casein. Zones were measured and compared sample 
with standard commercial drug streptokinase
27
. 
Fibrin plate method 
A mixture of 2.5 ml soluble fibrinogen (containing 
1.5% bovine fibrinogen in 20 mM Tris-HCl buffer pH 
4.7), 0.5 ml of thrombin solution (1 U / ml in 20 mM 
Tris-HCl buffer pH 4.7), 2.5 ml of 1% agarose and 
100 microliter human plasma was plated and some 
well created. Five mg of commercial drug 
streptokinase as standard and 5 mg of purified protein 
were poured in wells and incubated for 12 hours at 
37°C. Created cleared zone around the sample and 
standard wells were reviewed and interpreted
28
. 
Casein digestion method 
 Streptokinase activity determined by the casein 
digestion method which is based on the activation of 
tyrosine released from casein digestion after 
plasminogen activation
29
. Streptokinase activity was 
determined based on the modified previously 
described method. Briefly; a mixture of 0.1 mg casein, 
1.5 mg of purified recombinant mutant streptokinase, 
500 microliters of 50 mM Tris-HCl pH 8 was prepared 
and incubated at 37°C for one hour. Then one ml 
trichloro acetic acid (TCA) and 130 microliter of 3.3 
M HCl was added and placed on ice for 30 min. and 
centrifuged, the supernatant removed, and diluted at 
the ratio 1/4
30,31
. Absorbance of protein was measured 
at 280 nm. Streptokinase enzyme activity was 




Recombinant streptokinase gene was sub cloned into 
pET32a expression vector and transformed into E. coli 
BL21 (DE3) strain. Recombinant protein was 
expressed and purified by affinity chromatography S-
Tag system. Expressed and purified protein was 
refolded and its fibrinolytic activity was studied. 
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Figure 1 shows electrophoresis and zymography of 
purified protein on 12% SDS-PAGE gel. Protein 
concentration was 10 mg/ml. It was found that the 
more volume, more enzyme activity. 
Radial Caseinolytic activity 
Streptokinase qualitative activity was assessed using 
radial caseinolytic activity. Commercial 
streptokinase began to lysis casein and a halo with a 
diameter of more established at one hour, while the 
recombinant streptokinase start to lysis casein at 5 
hours and a cleared zone with a diameter of less 
developed (Figure 2). 
Fibrin plate method 
Streptokinase qualitative activity was assessed by 
Fibrin plate method. Commercial streptokinase started 
to lysis casein and a halo with a diameter of more 
established at two hours, while the recombinant 
streptokinase started to lysis casein at 5 hours and a 
cleared zone with a diameter of less developed (Figure 
3). 
Casein digestion method 
Digested casein absorbance at 280 nm was 0.888 and 




Clots in the circulatory system can cause blockage of 
blood vessels, brain-cardiac MI and ultimately lead to 
death. In such cases, thrombolytic or fibrinolytic 
agents such as streptokinase, tissue plasminogen 
activator and eurokinase, as blood clot-busting drugs 
are prescribed
3,33
. Among the three mentioned above 
drugs, streptokinase is cheaper than others.  
Streptokinase, a beta hemolytic streptococcus 
extracellular enzyme is a single polypeptide chain, 
composed of 414 amino acids with three structural 
domains, alpha, beta and gamma
34,35
. The gamma 
domain is essential for plasminogen activation. Alfa 




formation by streptokinase and plasminogen will 
hydrolysis the Arginine 561 and Valine 562 bond and 
convert plasminogen to plasmin. Plasmin can also 
cause degradation of soluble fibrin clots
37
. Non-human 
source streptokinase is immunogenic and stimulates 
the immune system. Production of neutralizing 
antibodies is leading to a massive allergic reaction
3,33
. 
There were some researches to reduce the 
immunological effects of streptokinase
17,38-40
. Seyed et 
al. were prepared mutant recombinant streptokinase 
through genetic manipulation
22
. Bandehpour et al. 
showed that the OD of the antigen -antibody reaction 
by natural streptokinase in streptokinase consumers as 
chemotherapy is three times more than that of antigen–
antibody reaction by mutated antigen. In other words, 
removal of the C-terminal 42 amino acids of the 
streptokinase reduces the immunogenicity
20
. Similar 
findings have been reported by Torrens et al.
38,39
. 









Figure 1. Fibrinolytic activity assay by zymography procedure on 
the 12% acrylamide gel; Lane 1- Control (commercial 
streptokinase), Lane 2 and 3- Recombinant-mutant streptokinase. 
 
 
Figure 2. Streptokinase qualitative activity by Radial 
Caseinolytic activity. 
Mobarrez et al.                                                                                     Fibrinolytic Activity of Recombinant Mutant Streptokinase 
NBM                                                                            92                                   Novelty in Biomedicine 2015, 2, 89-93 
They showed that less antibody by truncated 
streptokinase, whereas fibrinolytic activity is even 
higher, although clot lysis is slower
 41
. Streptokinase 
does not directly digest the blood clot, but it involved 
in the blood clots digestion by plasminogen 
activation. Nihalani believed that N-terminal amino 
acids of streptokinase are involved in plasminogen 
activation
10
. There is no problem for plasminogen 
activation of the studied mutant streptokinase 
because its N-terminal amino acids are intact. Tharp 
et al. replaced basic (Arg253, Lys256, and Lys257) 
and acidic (Glu249, Glu262, and Glu263) residues of 
250-loop of the streptokinase beta-domain with 
alanine, and proposed that streptokinase-plasminogen 
complex is formed when plasminogen identified 
streptokinase through Arg253, Lys256, and 
Lys257
42
. Mutated streptokinase contained Arg253, 
Lys256, and Lys257 and could plasminogen - 
streptokinase complex. 
Conclusion 
We concluded that mutant streptokinase has 
enzyme activity and was found that more volume 
and more enzymatic activity. 
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